Profound Medical (PROF) AI Stock Analysis
Profound Medical
(NASDAQ:PROF)
No summary available
Profound Medical (PROF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $335.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 192.74K
- Price to Earnings (P/E)
- -6.8
- Beta (1Y)
- 0.95
- Revenue Growth
- 61.19%
- EPS Growth
- 32.01%
- Country
- US
- Employees
- 162
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Profound Medical Business Overview & Revenue Model
Company Description
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroi...
Profound Medical Earnings Call Summary
The call conveyed strong commercial and clinical momentum: improving revenue trends (when adjusted for a one-time shipment timing shift), high gross margins, declining operating expenses, a growing $70M qualified sales pipeline, expanding payer coverage (Q1+Q2 added ~26.8M covered lives and Medicare tailwinds), and compelling randomized clinical evidence (CAPTAIN) that differentiates TULSA on quality-of-life outcomes. Challenges include a $3.1M revenue recognition timing slip, short-term utilization dips at a few sites during model transitions, installation/logistics lags, a proposed ASC reimbursement reduction to monitor, and continued net losses though improving. On balance, the positives — notably the sizable pipeline, reimbursement tailwinds, high margins, and strengthening clinical data — materially outweigh the operational and timing headwinds.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company reiterated full‑year 2026 revenue guidance of approximately $25.0M (≈56% growth vs. 2025) and expects full‑year gross margin to remain at 70%+; Q2 revenue was $2.5M (recurring $1.6M; capital $0.871M), up 12% YoY (but would have been ≈$5.6M, +153% YoY, excluding a $3.1M shipment timing shift), Q2 gross margin ~78% (vs. ~73% prior year), total operating expenses $13.0M (down 16% from $15.4M), net loss $9.5M or $0.26/share (vs. ~$15.7M or $0.52/share), and cash of $38.3M at June 30, 2026; installs totaled 84 TULSA PRO systems at quarter end, the qualified sales pipeline is ≈$70M (≈90% TULSA/10% Sonalleve; ~70% U.S./30% international), Index‑20 utilization was -12% sequential but +39% H1‑2026 vs H1‑2025 (+22% YoY), July set a monthly orders record and SRS generated ~160 qualified leads, coverage expanded by ~18.3M lives in Q2 (≈8.5M in Q1; ~30M total covered lives excluding Medicare), and CMS’s proposed 2027 OPPS would pay $15.5K/procedure for TULSA (+14.9%), versus $10.8K for HIFU and $12.3K for Aquablation (TULSA +44% vs HIFU/Aquablation; +26% or ~$3.19K vs robotic RP); ASC proposed payment is $6.87K and physician payment ~$880 for TULSA (vs $865 HIFU, $1,060 robotic RP, $539 Aquablation).
Profound Medical Risk Analysis
Profound Medical disclosed 68 risk factors in its most recent earnings report. Profound Medical reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksProfound Medical Peers Comparison
Overall Rating
TSE:ASG47Neutral
TSE:VPT46Neutral
TSE:TLT41.2Neutral
TSE:PINK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:ASG | 47Neutral | CAD 8.98M | -5.36 | -34.32% | ― | -5.42% | -5.37% |
| TSE:VPT | 46Neutral | CAD 15.43M | -6.13 | 56.40% | ― | 89.06% | 37.62% |
| TSE:TLT | 41Neutral | CAD 55.89M | -12.68 | -130.04% | ― | -24.86% | 18.29% |
| TSE:PINK | 38Underperform | CAD 27.62M | -1.41 | -303.05% | ― | 35.27% | 58.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PROF | Profound Medical | 6.57 | 0.61 | 10.23% | |
| TSE:ASG | Aurora Spine | 0.12 | -0.17 | -58.93% | |
| TSE:PINK | Perimeter Medical Imaging Ai Inc | 0.18 | -0.05 | -23.40% | |
| TSE:TLT | Theralase Technologies | 0.18 | -0.02 | -10.00% | |
| TSE:VPT | VentriPoint Diagnostics | 0.08 | -0.02 | -20.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.